Age-related heterogeneity in neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination

Dami A. Collier[1,2,3]*, Isabella A.T.M. Ferreira*[1,2] , Rawlings Datir [1,2,3], Bo Meng[1,2], Laura Bergamaschi[1,2], The CITIID-NIHR BioResource COVID-19 Collaboration[3], Anne Elmer[4], Nathalie Kingston[5], Barbara Graves [5], Kenneth GC Smith [1,2], John R. Bradley [2,5], Paul A. Lyons[1,2], Lourdes Ceron-Gutierrez[6], Gabriela Barcenas-Morales [6,7], Rainer Doffinger[6], Mark Wills[1,2] , Ravindra K. Gupta[1,2]

Paulina Cortes-Acevedo to add
Paulina Cortes-Acevedo
pau_corace@hotmail.com

(same affliation as Gabriela)

[1]Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
[2]Department of Medicine, University of Cambridge, Cambridge, UK.
[3]Division of Infection and Immunity, University College London, London, UK.
[4]The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix 1 for author list
[5]NIHR Cambridge Clinical Research Facility, Cambridge, UK.
[6]Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK
[7] Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico

Correspondence to:
Ravindra K. Gupta
Cambridge Institute for Therapeutic Immunology and Infectious Diseases
Jeffrey Cheah Biomedical Centre
Cambridge Biomedical Campus
Puddicombe Way
Cambridge CB2 0AW

Tel: 441223331491 rkg20@cam.ac.uk

Or

Mark Wills

Department of Medicine

Level 5 Addenbrookes Hospital

Cambridge, CB20QQ

Tel: 441223 336862 mrw1004@cam.ac.uk

Or

Rainer Doffinger

Department of Clinical Biochemistry and Immunology

Addenbrookes Hospital

Cambridge, CB20QQ

rd270@medschl.cam.ac.uk

Key words: SARS-CoV-2; COVID-19; antibody; vaccine; neutralising antibodies;

Abstract

Background

Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic. mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by a three to four week gap. UK policy in 2021 is to extend the dosing interval from three to twelve weeks. There is a paucity of data in the elderly, even though these individuals are the first to receive vaccines due to risk of severe disease. Here we assessed real world immune responses following vaccination with mRNA-based vaccine BNT162b2.

Methods:

We did a prospective cohort study of individuals presenting for first dose vaccination. Following the first and second doses of the BNT162b2 vaccine, we measured IFNγ T cell responses, as well as binding antibody (IgA, IgG and IgG1-4) responses to Spike and Spike RBD. We also measured neutralising antibody responses to Spike in sera using a lentiviral pseudotyping system. We correlated age with immune responses and compared responses after the first and second doses.

Findings

Median age was 63.5 years amongst 42 participants. Three weeks after the first dose a lower proportion of participants over 80 years old achieved adequate neutralisation titre of >1:20 for 50% neutralisation as compared to those under 80 (8/17 versus 19/24, p=0.03). Geometric mean neutralisation titres in this age group after the first dose were lower than in younger individuals (p<0.001). Binding IgA and IgG1 and 3 responses developed post vaccination, as observed in natural infection. T- cell responses were not different in those above or below 80 years. Following the second dose, 50% neutralising antibody titres were above 1:20 in all individuals and there was no longer a difference by age grouping.

Interpretation

A high proportion of individuals above the age of 80 have suboptimal neutralising antibody responses following first dose vaccination with BNT162b2, cautioning against extending the dosing interval in this high risk population.

Research in Context

Evidence before this study

We searched PubMed for research articles published from June 1st 2020 until February 8th 2021. We limited our search to English language papers. We used the following terms: “SARS-CoV-2” AND “vaccine” OR “BNT162b2” OR “Pfizer/BioNTech”. We identified only one paper. It showed lower neutralising antibody responses following the first dose of BNT162b in a small group of 12 individuals over 65 compared to those under 65. There were no data for patients above 82 years of age and no data on T cell responses by age. We did not find pre-prints on age related heterogeneity in individuals immunised with the Pfizer/BioNtech mRNA vaccine.

What this study adds

We show real world immune responses in forty two individuals to BNT162b2, spanning both T and B cell arms. We show that a high proportion of individuals above the age of 80 have suboptimal neutralising antibody responses following first dose vaccination with BNT162b2. The second dose generates robust responses in these poor responders. We quantify SARS-CoV-2 Spike and receptor binding domain (RBD) IgA and IgG isotypes as well as IgG subclasses. Finally we show that SARS-CoV-2 specific T cell responses are robustly induced by first dose vaccination and are not impacted by age.

Implications of all the available evidence

These data caution against extending the dosing interval of BNT162b2 in the elderly population, particularly during periods of high transmission, and also where there is risk of infection with variants that are less susceptible to vaccine-elicited neutralising antibodies.

Background

Vaccines designed to elicit protective immune responses remain the key hope for containing the SARS-CoV-2 pandemic. In particular, mRNA vaccines have shown promise in clinical trials and have used a two-dose approach, separated by a three or four week gap[1,2]. However, duration of protection is not known and clinical trials provide few data on neutralising responses or efficacy in individuals above the age of 80. For example there were only twelve patients above the age of 65 evaluated for neutralising responses in a Pfizer vaccine study[3]. This is pertinent for settings where a dosing interval of twelve weeks is currently being used to maximise first dose administration[4]. Data on vaccine responses are vital in order to understand the efficacy of vaccination using this regime, particularly in groups under-represented in clinical trials, such as those aged above 80 years who are at greatest risk of severe disease and death[5].

Here we assessed real world immune responses following vaccination with mRNA-based vaccine BNT162b2 under the recommended two-dose, three weeks apart schedule[1] in a predominantly elderly population. This schedule was used at the start of the vaccination programme in the UK, before a change to prioritise the first doses of vaccine for as many people as possible. We measured T cell responses to SARS-CoV-2 peptides by IFNγ FluoroSpot, in addition to serum IgG Spike/ RBD antibodies and serum neutralising antibody responses following the first and second doses of the BNT162b2 vaccine. We also linked neutralising antibody responses following vaccination to rapid antibody testing.

Results

Forty two participants received at least one vaccination and median age was 63.5 years (IQR 53.5-84.0), and 33% were female. T cell responses did not correlate with serum neutralisation after either dose (Figure 1 and 2). Age was correlated with serum neutralisation after the first but not second dose (Figure 1 and 3).

PBMC were stimulated with overlapping peptide pools to the SARS-CoV-2 Spike in addition to Cytomegalovirus, EBV and Flu (CEF+) peptide pools in an IFN gamma FluoroSpot assay to enumerate spike specific T cells. Following the first dose of vaccine only 2/27 participants had no detectable spike specific T cells (Figure 2); of the remainder the average response was 106 SFU/million CD3+ T cells and median 55.1 (range 8.5-586). However, there was no statistical difference in responses between <80 and >80 years of age groups (Figure 2, Supplementary Figure 1). Following the second dose only 1/20 individuals had no detectable spike specific T cells. The participant did not have a detectable response following the first dose; of the remainder the average response was 598 SFU/million CD3+ T cells and median 320 (range 29.6-5811), a statistically significant increase from first to second dose (Figure 2). Similar to the first dose, second dose T cell responses showed no statistical difference between <80 and >80 year groups. As expected, T cell responses to positive control stimulations and responses to CEF+ peptide stimulation were overlapping between dose 1 and 2 (Figure 2). Of the 16/20 participants tested following a second dose had increased T cell responses, with variable fold change between participants.

Binding antibody responses were comprehensively measured using a particle based assay. IgA responses were detected both in convalescent sera and after both doses, with small increase between the two time points (Figure 3A). IgG subclasses were also measured; IgG1and IgG3 against Spike and RBD increased between vaccine doses, as also observed in cases of natural infection (Figure 3B). IgG2 and 4 showed minimal increases. Spike specific IgA and IgG correlated with neutralisation (Figure 3C), as did IgG1 subclass (Supplementary Figure 2).

Sera from vaccinated individuals exhibited an increase in neutralizing titres against pseudoviruses expressing wild-type SARS-CoV-2 Spike protein between the first and second doses (Figure 4A, B). We observed poor neutralisation activity (<50% neutralisation at serum dilution of 1:20) almost exclusively in participants over the age of 80 (9/17) as compared to those under 80 (5/24) after the first dose (Figure 4C,D $p=0.03$). Geometric mean neutralisation titres in the over 80 years group after the first dose were substantially lower than in younger individuals (Figure 3C, $p<0.001$). Participant sera were re-tested three weeks after the second dose in all of those above 80 and in 5 of the 16 participants under 80 years old. Of the fourteen poor responders following the first dose of vaccine, all those re-tested

following second now demonstrated neutralisation activity comparable to those who responded well to the first dose. There was no statistically significant difference in neutralizing titres between participants above and below the age of 80 following the second dose (Figure 4C).

Discussion

Immune senescence is a well described phenomenon whereby responses to pathogens[6] and indeed vaccines are impaired/dysregulated with age[7]. As an example, effective seasonal influenza vaccination of the elderly is a significant public health challenge due to greater morbidity and mortality in this group. Lower neutralizing antibody titres using standard dose influenza vaccines in elderly individuals has been addressed by using higher doses vaccine [8]. As such it is not surprising that while a single dose of BNT162b2 failed to induce neutralizing antibodies in a proportion of participants, a second dose 3 weeks later resulted in all participants mounting a neutralizing antibody response.

Here we have addressed an important aspect of rollout of vaccination against SARS-CoV-2, where the second dose may be delayed due to supply limitations. We have shown that almost half of individuals above the age of 80 have a suboptimal neutralising antibody response three weeks after vaccination with BNT162b2, and that the second dose is associated with robust neutralising responses. T cell responses were generally good across age groups following first dose, though lower in the over 80 age group. Binding IgA antibodies to Spike and RBD increased following the first and second doses, mirroring levels seen in natural infection. IgG3 responses to Spike and RBD increased predominantly after the second dose; this subclass has been associated with multifunctional antibody responses.

In a clinical study specifically looking at older adults vaccinated with BNT162b2 the GMT (geometric mean titre) after first dose was 12 in a set of 12 subjects between ages of 65 and 85 years, rising to 149 seven days after the second dose [3]. Whilst the GMT after second dose was lower in older subjects, the data for first dose were unclear, possibly due to neutralisation assay characteristics. Furthermore, in the Moderna 1273 mRNA vaccine study in older individuals (above 55 years), neutralisation was only detectable after the second dose, whilst binding antibodies were detectable after both doses[9]. Interestingly, in aged mice the ChAdOx

nCov-19 vaccine responses were lower as compared to younger mice, and this was overcome by booster dosing[10].

The ChAdOx nCov-19 vaccine was reported as being effective even with a twelve week gap between the two doses (Emery et al, SSRN 2021). However this study was in younger individuals, and would be consistent with neutralising responses in those under 80 in our study. It is possible that the suboptimal responses we observed may improve after 3 weeks in older individuals. Even if this is the case, individuals over 80 are nonetheless likely to be at prolonged increased risk for infection, based on studies in non-human primates linking protection from SARS-CoV-2 challenge with neutralising antibody titres, but not T cell responses [11,12]. In further support for the role of neutralising antibodies are two clinical studies: (i) use of early convalescent sera in COVID-19 disease within elderly patients demonstrating improved clinical outcomes[13] and (ii) the recent report of suboptimal efficacy of the ChAdOx nCov-19 vaccine against prevention of mild to moderate COVID-19 in the context of the variant 501Y.V3 (https://www.theguardian.com/society/2021/feb/07/covid-vaccine-booster-variants-emerge-minister). Although the second dose was able to boost neutralising antibodies, SARS-CoV-2 infection during an enlarged window period between doses in the presence of only partially protective antibody titres could also lead to favourable conditions for selecting escape mutations[14,15].

It will be important to follow all participants over the following months to measure the kinetics of neutralisation activity as well as to gather data on re-infection. The arrival of new variants with the potential to compromise vaccines[16-19] may mandate regular re-vaccination with modified vaccine preparations.

Limitations

This study was limited by a small sample size, though of note the numbers of elderly participants undergoing assessment for neutralisation and T cell responses was greater than manufacturer-sponsored vaccine studies[3, 9]. We were also not able to ascertain prior infection in our participants. The lack of neutralisation in a significant proportion of the over 80 group argues against prior infection in the poor responders. Finally, we did not measure neutralising antibody responses beyond three weeks in the absence of a second dose in individuals over the age of 80.

Conclusion

Whilst significant public health impact of vaccines is anticipated, a significant proportion of individuals above 80 appear to require the second dose, which in this study was given at three weeks, to achieve in vitro virus neutralisation. Independent verification of these findings is needed. Nonetheless, our data caution against extending the dosing interval of BNT162b2 in the elderly population, particularly during periods of high transmission, where there is the added risk from variants that are less susceptible to vaccine-elicited neutralising antibodies[16,17,19,20].

Acknowledgements

We would like to thank Cambridge University Hospitals NHS Trust Occupational Health Department. We would also like to thank the NIHR Cambridge Clinical Research Facility and staff at CUH, Eleanor Lim and Georgina Okecha and the level 5 Medicine team (Wills and Sinclair labs). We would like to thank James Nathan, Leo James and John Briggs. We thank Dr James Voss for the kind gift of HeLa cells stably expressing ACE2. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. KGCS is the recipient of a Wellcome Investigator Award (200871/Z/16/Z). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU), the NIHR BioResource and Addenbrooke's Charitable Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. JAGB is supported by the Medical Research Council (MC_UP_1201/16). IATM is funded by a SANTHE award.

Table 1: Characteristics of study participants

	≤80 YEARS N =24	**>80 YEARS N=18**	**P VALUE**
FEMALE (%)	33.3 (8)	33.3 (6)	<0.0001[a]
MEDIAN AGE (IQR) *YEARS*	44.5 (54.0-58.5)	82.0 (84.0-87.0)	
GEOMETRIC MEAN TITRE (95% CI)			
DOSE 1	79.9 (35.9-177.6)	19.9 (10.4-38.0)	0.01[b]
DOSE 2	651.0 (155.6-2722.9)	555.1 (351.5-876.5)	1.00[b]
PROPORTION WITH			

DETECTABLE NEUTRALISATION ID50>20 (%)	79.2 (19)	44.4 (8/17*)	0.03[a]

a Chi-square test
b Wilcoxon rank-sum test
*neutralisation data unavailable for one individual

MATERIALS AND METHODS

Participant recruitment and ethics

Participants who had received the first dose of vaccine and individuals with COVID-19 were consented into the Covid-19 cohort of the NIHR Bioresource. The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).

SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex):

Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to distinct carboxylated bead sets (Luminex; Netherlands) to form a 3-plex and analyzed as previously described[21]. Specific binding was reported as mean fluorescence intensities (MFI).

Neutralisation assays

Spike pseudotype assays have been shown to have similar characteristics as neutralisation testing using fully infectious wild type SARS-CoV-2[22]. Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 Spike pseudotyped virus expressing luciferase[23]. Pseudotyped virus was incubated with serial dilution of heat inactivated human serum samples or sera from vaccinees in duplicate for 1h at 37˚C. Virus and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5% CO_2 environment at 37°C, luminescence was measured using the Steady-Glo Luciferase assay system (Promega).

IFNγ FLUOROSPOT assays

Frozen PBMCs were rapidly thawed, and the freezing medium was diluted into 10ml of TexMACS media (Miltenyi Biotech), centrifuged and resuspended in 10ml of fresh media with 10U/ml DNase (Benzonase, Merck-Millipore via Sigma-Aldrich), PBMCs were incubated at 37°C for 1h, followed by centrifugation and resuspension in fresh media supplemented with 5% Human AB serum (Sigma Aldrich) before being counted. PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4-phycoerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll protein - cyanine 5.5 (PerCP Cy5.5), clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). PBMC phenotyping was performed on the BD Accuri C6 flow cytometer. Data were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK). 1.0 to 2.5 x 105 PBMCs were incubated in pre-coated Fluorospot plates (Human IFNγ FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden)) in triplicate with peptide mixes specific for Spike, Nucleocapsid and Membrane proteins of SARS-CoV-2 (final peptide concentration 1µg/ml/peptide, Miltenyi Biotech) and an unstimulated and positive control mix (containing anti-CD3 (Mabtech AB), Staphylococcus Enterotoxin B (SEB), Phytohaemagglutinin (PHA) (all Sigma Aldrich)) at 37ºC in a humidified CO2 atmosphere for 48 hours. The cells and medium were decanted from the plate and the assay developed following the manufacturer's instructions. Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany). All data were then corrected for background cytokine production and expressed as SFU/Million PBMC or CD3 T cells.

Statistical analysis

Linear regression was used to explore the association between antibody response, T cell response and serum neutralisation in Stata 13. The Pearson correlation coefficient was reported.

Neutralisation

Neutralization was calculated relative to virus only controls. Dilution curves were presented as a mean neutralization with standard error of the mean (SEM). IC50 values were calculated in GraphPad Prism. The IC50 withing groups were summarised as a geometric mean titre and statistical comparison between groups were made with Wilxocon ranked sign test. In addition, the impact of the mutations on the neutralising effect of the sera were expressed as

fold change of ID50 of the wild-type compared to mutant pseudotyped virus. Statistical difference in the mean FC between groups was determined using a 2-tailed t-test

IFNγ FluoroSpot assays

The association between Spike Tcell response, Spike specific antibody response and serum neutralisation was determined using linear regression and the Pearson correlation coefficient between these variables were determined using Stata 13.

References

1 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).

2 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2020).

3 Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *New England Journal of Medicine* **383**, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).

4 Health, D. o. *Briefing on rescheduling of second doses of the Pfizer/BioNTech Covid-19 vaccine*, <https://www.health-ni.gov.uk/news/briefing-rescheduling-second-doses-pfizerbiontech-covid-19-vaccine> (2021).

5 Docherty, A. B. *et al.* Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* **369**, m1985, doi:10.1136/bmj.m1985 (2020).

6 Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. *Science* **369**, 256-257, doi:10.1126/science.abb0762 (2020).

7 Haq, K. & McElhaney, J. E. Immunosenescence: Influenza vaccination and the elderly. *Curr Opin Immunol* **29**, 38-42, doi:10.1016/j.coi.2014.03.008 (2014).

8 Izurieta, H. S. *et al.* Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. *Lancet Infect Dis* **15**, 293-300, doi:10.1016/S1473-3099(14)71087-4 (2015).

9 Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine* **383**, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).

10 Silva-Cayetano, A. *et al.* A Booster Dose Enhances Immunogenicity of the COVID-19 Vaccine Candidate ChAdOx1 nCoV-19 in Aged Mice. *Med (N Y)*, doi:10.1016/j.medj.2020.12.006 (2020).

11 Roozendaal, R. *et al.* SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques. *bioRxiv*, 2021.2001.2030.428921, doi:10.1101/2021.01.30.428921 (2021).

12 Mercado, N. B. *et al.* Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature* **586**, 583-588, doi:10.1038/s41586-020-2607-z (2020).

13 Libster, R. *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *New England Journal of Medicine*, doi:10.1056/NEJMoa2033700 (2021).
14 Kemp, S. A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature*, doi:10.1038/s41586-021-03291-y (2021).
15 Choi, B. *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med*, doi:10.1056/NEJMc2031364 (2020).
16 Kemp, S. *et al.* Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. *bioRxiv*, 2020.2012.2014.422555, doi:10.1101/2020.12.14.422555 (2021).
17 Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034, doi:10.1101/2020.12.30.20249034 (2021).
18 Cele, S. *et al.* Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. *medRxiv*, 2021.2001.2026.21250224, doi:10.1101/2021.01.26.21250224 (2021).
19 Tegally, H. *et al.* Major new lineages of SARS-CoV-2 emerge and spread in South Africa during lockdown. *medRxiv*, 2020.2010.2028.20221143, doi:10.1101/2020.10.28.20221143 (2020).
20 Collier, D. A. *et al.* SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies. *medRxiv*, 2021.2001.2019.21249840, doi:10.1101/2021.01.19.21249840 (2021).
21 Xiong, X. *et al.* A thermostable, closed SARS-CoV-2 spike protein trimer. *Nature Structural & Molecular Biology* **27**, 934-941, doi:10.1038/s41594-020-0478-5 (2020).
22 Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
23 Mlcochova, P. *et al.* Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant. *Cell Rep Med*, 100099, doi:10.1016/j.xcrm.2020.100099 (2020).



Figure 1: Immune responses after the first and second doses of Pfizer BNT162b2 vaccine. First dose A, B. A. correlation between serum neutralisation of Spike (D614G) pseudotyped lentiviral particles (inhibitory dilution at which 50% inhibition of infection is achieved, ID50) and T cell responses against SARS-CoV-2 by IFN gamma FLUOROSPOT. B. Correlation between age and serum neutralisation of Spike (D614G) pseudotyped lentiviral particles. **Second dose C,D** as for A, B. SFU: spot forming units. r: correlation coefficient with p value indicated and b the slope or coefficient.



Figure 2. T cell responses to Pfizer BNT162b2 vaccine. A. FluoroSpot interferon gamma T cell responses to SARS-CoV-2 peptide pool three weeks after the first and three weeks after second doses of Pfizer BNT162b2 vaccine. B. FluoroSpot interferon gamma T cell responses stratified by age <>80 years old. Also shown are positive control (PHA). CEF peptide pool (comprising peptides from influenza, CMV, EBV SARS-CoV-2)



Figure 3: Binding antibody responses following vaccination with Pfizer BNT162b2 vaccine across serial serum dilutions. A. IgA responses to S, N, RBD post first (light green) and second dose (dark green) compared to individuals with prior infection (red) and negative controls (grey) B. IgG subclass responses to S, N, RBD post first and second dose compared to individuals with prior infection. C. Correlations between binding antibody responses and neutralisation by vaccine sera against SARS-CoV-2 in a Spike lentiviral pseudotyping assay expressing wild type Spike (D614G). MFI – mean fluorescence intensity. S – Spike, N – nucleocapsid, RBD – Spike receptor binding domain



D



Figure 4. A-C. Neutralisation by Pfizer BNT162b2 vaccine sera against SARS-CoV-2 in a Spike lentiviral pseudotyping assay expressing wild type Spike (D614G). Data are shown as mean ID50 values for individuals three weeks after Dose 1 and three weeks after Dose 2. Geometric mean with standard error is shown. Each point is a mean of technical replicates. **D. Neutralisation curves for serum from six individuals with reduced responses after first dose of Pfizer BNT162b2 vaccine** against pseudovirus expressing wild type Spike (D614G). Means of technical replicates are plotted with error bars representing standard error of mean. Data are representative of 2 independent experiments.



Supplementary Figure 1. FLUOROSPOT interferon gamma PBMC responses to SARS-CoV-2 peptide pool three weeks after the first and three weeks after second doses of Pfizer BNT162b2 vaccine. Also shown are positive control (PHA) and CEF peptide pool (comprising peptides from influenza, CMV, EBV SARS-CoV-2)





Supplementary Figure 2. Correlations between serum binding IgG subclass 1-4 antibody responses following vaccination with first dose of Pfizer BNT162b2 vaccine and serum neutralization using a pseudotyped viral system. ID50 – inhibitory dilution required to achieve 50% inhibition of viral infection.